Recombinant Human SCNN1A, N-His

Description of Recombinant Human SCNN1A, N-His

Introduction

Recombinant human scnn1a (short for sodium channel nonvoltage-gated 1 alpha subunit) is a protein that plays a crucial role in regulating sodium transport in the body. This protein is a drug target for various diseases and has been extensively studied for its structure, activity, and potential applications.

Structure of Recombinant Human scnn1a

The scnn1a protein is encoded by the SCNN1A gene, located on chromosome 12 in humans. It is a member of the epithelial sodium channel (ENaC) family, which also includes scnn1b and scnn1g. The scnn1a protein consists of 684 amino acids and has a molecular weight of approximately 78 kDa.

The protein has two transmembrane domains, which form the pore through which sodium ions pass, and two extracellular domains, which are responsible for binding to aldosterone, a hormone that regulates sodium levels in the body. The structure of scnn1a is highly conserved among different species, indicating its importance in sodium transport.

Activity of Recombinant Human scnn1a

The main function of scnn1a is to facilitate the movement of sodium ions across cell membranes. This process is essential for maintaining fluid balance, blood pressure, and electrolyte levels in the body. The scnn1a protein is primarily found in the kidney, lung, and colon, where it is involved in sodium absorption and secretion.

The activity of scnn1a is tightly regulated by various factors, including hormones, pH levels, and other proteins. For example, aldosterone stimulates scnn1a to increase sodium reabsorption in the kidney, while prostasin, a serine protease, activates scnn1a to enhance sodium absorption in the lung.

Applications of Recombinant Human scnn1a

As a drug target, scnn1a has been studied for its potential in treating various diseases related to sodium imbalance. Mutations in the SCNN1A gene have been associated with a rare genetic disorder called Liddle syndrome, characterized by hypertension and low potassium levels. Inhibiting scnn1a activity has been proposed as a potential treatment for this condition.

Additionally, scnn1a has been implicated in the development and progression of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. In cystic fibrosis, scnn1a is overactive, leading to increased sodium absorption and thickening of mucus in the airways. Inhibitors of scnn1a have shown promise in reducing mucus production and improving lung function in cystic fibrosis patients.

Furthermore, scnn1a has been studied as a potential target for hypertension, as it plays a crucial role in regulating blood pressure. Inhibitors of scnn1a have been shown to reduce blood pressure in animal models, making it a promising target for the treatment of hypertension.

Conclusion

Recombinant human scnn1a is a protein that plays a vital role in sodium transport and is a drug target for various diseases. Its structure, activity, and potential applications have been extensively studied, and it holds promise for the treatment of conditions such as Liddle syndrome, cystic fibrosis, and hypertension. Further research on scnn1a and its inhibitors may lead to the development of new and effective treatments for these diseases.